Yildiz Mehmet Metin, Petersen Iver, Eigendorff Ekkehard, Schlattmann Peter, Guntinas-Lichius Orlando
Department of Otorhinolaryngology, Jena University Hospital, Lessingstrasse 2, 07740, Jena, Germany.
Institute of Pathology, Jena University Hospital, Jena, Germany.
J Cancer Res Clin Oncol. 2016 Apr;142(4):885-93. doi: 10.1007/s00432-015-2104-1. Epub 2015 Dec 28.
To investigate the best lymph node (LN) metastasis predictor for overall survival (OS) in head neck cancer (HNC): pN classification, number of positive lymph nodes (PNOD), lymph node ratio (LNR), or log odds of positive lymph nodes (LODDS).
In total, 225 surgically treated HNC patients were evaluated for the different LN classifications and OS.
Five-year OS was 71.8 %. Mean number of yielded LN and PNOD was 25.3 ± 16.7 and 2.7 ± 5.9, respectively. 64.8 % had a LNR > 0.10 and 64.4 % a LODDS > 10. In univariable analysis, multimodal therapy (p = 0.039), advanced pT (p < 0.0001), advanced UICC stage (p = 0.029), LNR > 0.10 (p = 0.049), and LODDS > -1.0 (p = 0.021) were associated with lower OS. In multivariable analysis, advanced pT [hazard ratio (HR) 2.194; 95 % confidence interval (CI) 1.294-3.722; p = 0.004] and LODDS > -1.0 (HR 1.634; 95 % CI 1.002-2.665; p = 0.059) remained independent predictors for lower OS.
It seems useful to analyze the prognostic significance of LODDS in other samples of HNC.
探讨头颈部癌(HNC)中总生存(OS)的最佳淋巴结(LN)转移预测指标:pN分类、阳性淋巴结数量(PNOD)、淋巴结比率(LNR)或阳性淋巴结对数比值(LODDS)。
共评估了225例接受手术治疗的HNC患者的不同LN分类和OS。
5年总生存率为71.8%。平均获取的LN数量和PNOD分别为25.3±16.7和2.7±5.9。64.8%的患者LNR>0.10,64.4%的患者LODDS>10。单因素分析中,多模式治疗(p = 0.039)、晚期pT(p < 0.0001)、晚期国际抗癌联盟(UICC)分期(p = 0.029)、LNR>0.10(p = 0.049)和LODDS>-1.0(p = 0.021)与较低的OS相关。多因素分析中,晚期pT[风险比(HR)2.194;95%置信区间(CI)1.294 - 3.722;p = 0.004]和LODDS>-1.0(HR 1.634;95%CI 1.002 - 2.665;p = 0.059)仍然是较低OS的独立预测指标。
分析LODDS在其他HNC样本中的预后意义似乎是有用的。